The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy.
Mogensen CE, Christensen CK, Vittinghus E.
Diabetes. 1983 May;32 Suppl 2:64-78. doi: 10.2337/diab.32.2.s64.
Diabetic nephropathy.
Ibrahim HA, Vora JP.
Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Jul;13(2):239-64. doi: 10.1053/beem.1999.0018.
Diabetic nephropathy.
Ritz E.
Saudi J Kidney Dis Transpl. 2006 Dec;17(4):481-90.
ESRRA-ATG5-Mediated mitophagy enhances arginine metabolism to alleviate diabetic kidney disease.
Hu H, Yang Q, Hu J, Fan Y, Zhang Z, Yang K, Li W, Peng Z, Chen Z, Ding G, Liang W.
Autophagy. 2026 Apr;22(4):666-690. doi: 10.1080/15548627.2025.2601874. Epub 2025 Dec 23.
Clinical practice: proteinuria.
Ariceta G.
Eur J Pediatr. 2011 Jan;170(1):15-20. doi: 10.1007/s00431-010-1334-0. Epub 2010 Nov 10.
Pathogenesis of diabetic nephropathy.
Raptis AE, Viberti G.
Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S424-37. doi: 10.1055/s-2001-18600.
Investigational drugs for diabetic nephropathy.
Cortinovis M, Cattaneo D, Perico N, Remuzzi G.
Expert Opin Investig Drugs. 2008 Oct;17(10):1487-500. doi: 10.1517/13543784.17.10.1487.
Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.
Parving HH.
J Hypertens Suppl. 1998 Jan;16(1):S99-101.
Lipoprotein abnormalities in diabetic nephropathy.
Hirano T.
Kidney Int Suppl. 1999 Jul;71:S22-4. doi: 10.1046/j.1523-1755.1999.07106.x.
Effect of direct renin inhibitor monotherapy on proteinuria in overt diabetic nephropathy.
Silaratana S, Sumransurp S, Duangchana S, Tasanarong A.
J Med Assoc Thai. 2012 Jan;95 Suppl 1:S18-23.
